Overview

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

Status:
Unknown status

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

In this trial, the investigators will test the combination of escalating doses of chemotherapy (starting at relatively low dose) with lenalidomide in intermediate-2-or high risk MDS and AML with del 5 q31. It is hoped that this combined therapy will further increase response rate in intermediate-2-or high risk MDS and AML with del 5 q31, without major toxicity in comparison to historical results obtained with chemotherapy alone in the same subset of patients.

Phase:

Phase 2

Details

Lead Sponsor:

Groupe Francophone des Myelodysplasies

Collaborator:

Celgene Corporation

Treatments:

Lenalidomide
Thalidomide